In a trial comparing survival in patients with unresectable late-stage BRAF V600E or V600K-mutated melanoma receiving either combination therapy of dabrafenib and trametinib and those receiving dabrafenib and placebo, Long et al. concluded that combination therapy reduced the risk of disease progression by 25% and improved response [24]. Here, BRAF is linked to melanoma.